WO2007021970A3 - Formes pharmaceutiques stables et methodes d'utilisation de celles-ci - Google Patents

Formes pharmaceutiques stables et methodes d'utilisation de celles-ci Download PDF

Info

Publication number
WO2007021970A3
WO2007021970A3 PCT/US2006/031439 US2006031439W WO2007021970A3 WO 2007021970 A3 WO2007021970 A3 WO 2007021970A3 US 2006031439 W US2006031439 W US 2006031439W WO 2007021970 A3 WO2007021970 A3 WO 2007021970A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
pharmaceutical formulations
pharmaceutically active
stable pharmaceutical
pharmaceutical compositions
Prior art date
Application number
PCT/US2006/031439
Other languages
English (en)
Other versions
WO2007021970A2 (fr
Inventor
Heow Meng Tan
Ming Ye
Thomas F Mcgrath
Kevin A Johnston
Maria Micalizzi
Patrick Mckenna
Martin Patrick Redmon
Murali K Vuppala
Gary F Musso
Original Assignee
Praecis Pharm Inc
Heow Meng Tan
Ming Ye
Thomas F Mcgrath
Kevin A Johnston
Maria Micalizzi
Patrick Mckenna
Martin Patrick Redmon
Murali K Vuppala
Gary F Musso
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Praecis Pharm Inc, Heow Meng Tan, Ming Ye, Thomas F Mcgrath, Kevin A Johnston, Maria Micalizzi, Patrick Mckenna, Martin Patrick Redmon, Murali K Vuppala, Gary F Musso filed Critical Praecis Pharm Inc
Publication of WO2007021970A2 publication Critical patent/WO2007021970A2/fr
Publication of WO2007021970A3 publication Critical patent/WO2007021970A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention porte sur des formes pharmaceutiques caractérisées par une stabilité accrue des composés pharmaceutiquement actifs qu'elles contiennent, des procédés permettant de préparer ces formes, et des méthodes d'utilisation de ces dernières. Ces compositions pharmaceutiques décrites contiennent un complexe stable, insoluble dans l'eau, d'un composé pharmaceutiquement actif, et d'un véhicule macromoléculaire. Parmi les avantages des compositions pharmaceutiques décrites, on peut citer par exemple la stabilité accrue du composé pharmaceutiquement actif contenu dans les compositions. .
PCT/US2006/031439 2005-08-15 2006-08-14 Formes pharmaceutiques stables et methodes d'utilisation de celles-ci WO2007021970A2 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US70853605P 2005-08-15 2005-08-15
US60/708,536 2005-08-15
US73254505P 2005-11-02 2005-11-02
US60/732,545 2005-11-02
US79855506P 2006-05-08 2006-05-08
US60/798,555 2006-05-08

Publications (2)

Publication Number Publication Date
WO2007021970A2 WO2007021970A2 (fr) 2007-02-22
WO2007021970A3 true WO2007021970A3 (fr) 2008-10-09

Family

ID=37667924

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/031439 WO2007021970A2 (fr) 2005-08-15 2006-08-14 Formes pharmaceutiques stables et methodes d'utilisation de celles-ci

Country Status (1)

Country Link
WO (1) WO2007021970A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2060253A1 (fr) 2007-11-14 2009-05-20 Laboratorios Farmaceuticos Rovi, S.A. Formes pharmaceutiques pour la libération de composés actifs
DE102007003765A1 (de) * 2007-01-19 2008-07-24 Farco-Pharma Gmbh Pharmazeutische Zusammensetzung zur Behandlung von Inkontinenz
WO2009002481A1 (fr) * 2007-06-26 2008-12-31 Merck & Co., Inc. Composition antifongique lyophilisée
CN102697733B (zh) * 2007-12-04 2015-08-12 上海抗体药物国家工程研究中心有限公司 一种内包裹免疫毒素外连接抗体的聚乳酸-羟基乙酸共聚物纳米颗粒
US11963995B2 (en) 2008-05-21 2024-04-23 Ferring B.V. Methods comprising desmopressin
US20100286045A1 (en) 2008-05-21 2010-11-11 Bjarke Mirner Klein Methods comprising desmopressin
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
CN101810583B (zh) * 2010-04-09 2013-09-11 佟丽 Hiv融合抑制剂缓释微球
CN102580056B (zh) * 2011-12-16 2014-04-09 深圳市健元医药科技有限公司 一种含抗利尿成分的缓释注射剂及其制备方法
WO2015023675A2 (fr) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Comprimé extrudé anti-abus à libération immédiate
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2955229C (fr) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Forme posologique remplie de liquide anti-abus a liberation immediate
JP2017531026A (ja) 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 徐放性乱用抑止性液体充填剤形
EP3372247B1 (fr) * 2015-11-04 2022-01-05 Postech Academy-Industry Foundation Composition pour pénétration cutanée comprenant un transporteur moléculaire cationique et une protéine
CN106729717A (zh) * 2016-12-12 2017-05-31 深圳市健翔生物制药有限公司 Glp‑1类似物和齐考诺肽组合物缓释微球制剂
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025642A2 (fr) * 1996-12-11 1998-06-18 Praecis Pharmaceuticals Incorporated Formulations pharmaceutiques pour administration de medicaments a liberation prolongee
WO1999055358A1 (fr) * 1998-04-27 1999-11-04 Praecis Pharmaceuticals Incorporated Methodes de traitement des bouffees de chaleur et de la gynecomastie
WO2002022154A2 (fr) * 2000-09-13 2002-03-21 Praecis Pharmaceuticals Incorporated Compositions pharmaceutiques pour medicaments a liberation prolongee
WO2004056388A1 (fr) * 2002-12-19 2004-07-08 Praecis Pharmaceuticals, Inc. Methodes propres a renforcer la fonction du systeme immunitaire chez un sujet
WO2007022254A2 (fr) * 2005-08-15 2007-02-22 Praecis Pharmaceuticals, Inc. Preparations pharmaceutiques pour la liberation prolongee de medicaments

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998025642A2 (fr) * 1996-12-11 1998-06-18 Praecis Pharmaceuticals Incorporated Formulations pharmaceutiques pour administration de medicaments a liberation prolongee
US6180608B1 (en) * 1996-12-11 2001-01-30 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20030171296A1 (en) * 1996-12-11 2003-09-11 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
EP1398037A2 (fr) * 1996-12-11 2004-03-17 Praecis Pharmaceuticals Incorporated Formulations pharmaceutique pour administration de médicaments à libération prolongee
WO1999055358A1 (fr) * 1998-04-27 1999-11-04 Praecis Pharmaceuticals Incorporated Methodes de traitement des bouffees de chaleur et de la gynecomastie
WO2002022154A2 (fr) * 2000-09-13 2002-03-21 Praecis Pharmaceuticals Incorporated Compositions pharmaceutiques pour medicaments a liberation prolongee
WO2004056388A1 (fr) * 2002-12-19 2004-07-08 Praecis Pharmaceuticals, Inc. Methodes propres a renforcer la fonction du systeme immunitaire chez un sujet
WO2007022254A2 (fr) * 2005-08-15 2007-02-22 Praecis Pharmaceuticals, Inc. Preparations pharmaceutiques pour la liberation prolongee de medicaments

Also Published As

Publication number Publication date
WO2007021970A2 (fr) 2007-02-22

Similar Documents

Publication Publication Date Title
WO2007021970A3 (fr) Formes pharmaceutiques stables et methodes d'utilisation de celles-ci
WO2007022255A3 (fr) Preparations pharmaceutiques a liberation prolongee
WO2002074247A3 (fr) Formulations pharmaceutiques a liberation prolongee
WO2004074244A3 (fr) Composes de pyrimidine
WO2007146248A3 (fr) Préparations de laquinimod stables
WO2006068826A3 (fr) Inhibiteurs de la kinase erbb a base de 2-pyrimidinyle pyrazolopyridine
WO2007027941A3 (fr) Compositions et methode de preparation de medicaments a faible solubilite dans l'eau presentant une stabilite accrue
WO2007008752A3 (fr) Compositions pharmaceutiques a liberation prolongee pour medicaments tres solubles dans l'eau
WO2003037860A3 (fr) Analogues de purine presentant une activite inhibitrice de hsp90
WO2003095455A3 (fr) Composes therapeutiques
WO2002048147A3 (fr) Composes therapeutiques
MX2007014892A (es) Formas polimorficas del ester etilico del acido 3-[(2-{[4-(hexiloxicarbonilamino-imino-metil)-fenilamino]-metil}- 1-metil-h-bencimidazol-5-carbonil)-piridin-2-il--amino]propionico .
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
WO2006096444A3 (fr) Composes chimiques
WO2007044796A3 (fr) Composes de pyridazinone servant de calcilytiques
WO2007065595A3 (fr) Derives de la xanthine, procedes de preparation et utilisations de ceux-ci
WO2002048148A3 (fr) Composes therapeutiques
WO2009105969A8 (fr) Analogues d'épothilone, leurs compositions pharmaceutiques, leur utilisation et leurs préparations
WO2001095856A3 (fr) Derive d'uree en tant qu'agent anticancereux et son procede de preparation
WO2006117211A3 (fr) Derives d'uree, procedes pour leur fabrication et utilisations de ces derives
WO2004093800A3 (fr) Derives de thyronamine et analogues et des methodes d'utilisation de ces composes
WO2006072070A3 (fr) Formulations pharmaceutiques contenant des sels de gallium
MX2008001560A (es) Nuevos compuestos analogos de la camptotecina, un procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
WO2006134021A3 (fr) Procede de preparation de nouveaux sels de tiotropium, nouveaux sels de tiotropium en tant que tels et compositions pharmaceutiques associees
WO2009060952A1 (fr) Nouvelle préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIUGHTS PURSUANT TO RULE 112(1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 06801293

Country of ref document: EP

Kind code of ref document: A2